Supersaturated Self-Nanoemulsifying Drug Delivery Systems (Super-SNEDDS) Enhance the Bioavailability of the Poorly Water-Soluble Drug Simvastatin in Dogs

This study investigates the potential of supersaturated self-nanoemulsifying drug delivery systems (super-SNEDDS) to improve the bioavailability of poorly water-soluble drugs compared to conventional SNEDDS. Conventional SNEDDS contained simvastatin (SIM) at 75% of the equilibrium solubility (Seq). Super-SNEDDS containing SIM at 150 and 200% of Seq were produced by subjecting the SNEDDS preconcentrates to a heating and cooling cycle. The super-SNEDDS were physically stable over 10 months. During in vitro lipolysis of SNEDDS and super-SNEDDS the SIM concentration in the aqueous phase increased for the first 30 min almost proportional to the drug loads and amounts of preconcentrate employed. The 200% drug-loaded super-SNEDDS generated an amorphous SIM precipitate at the end of in vitro lipolysis. In vivo, the relative bioavailability of SIM from super-SEDDDS increased significantly to 180 ± 53.3% (p = 0.014) compared to the dosing of two capsules of (dose equivalent) 75% drug-loaded SNEDDS. A significant increase in the terminal half-life of elimination was observed for super-SNEDDS (2.3 ± 0.6 h) compared to conventional SNEDDS (1.4 ± 0.3 h) as well as a decreased area under the curve ratio of the SIM metabolite simvastatin acid to the parent compound (0.57 ± 0.20 and 0.90 ± 0.3), possibly due to a combination of saturation effects on presystemic metabolising enzymes and prolonged absorption along the small intestine. In summary, this study demonstrated that super-SNEDDS are a viable formulation option to enhance the bioavailability of poorly water-soluble drugs such as simvastatin while reducing the pill burden by an increased drug load of SNEDDS.

[1]  A. Serajuddin,et al.  Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. , 1991, Journal of pharmaceutical sciences.

[2]  Joachim Grevel,et al.  Improved Dose Linearity of Cyclosporine Pharmacokinetics from a Microemulsion Formulation , 1994, Pharmaceutical Research.

[3]  J. Turgeon,et al.  Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. , 1998, Trends in pharmacological sciences.

[4]  Fang Gao,et al.  The characteristics and mechanism of simvastatin loaded lipid nanoparticles to increase oral bioavailability in rats. , 2010, International journal of pharmaceutics.

[5]  A Müllertz,et al.  A dynamic in vitro lipolysis model. I. Controlling the rate of lipolysis by continuous addition of calcium. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[6]  T. Rades,et al.  Influence of lipid composition and drug load on the In Vitro performance of self-nanoemulsifying drug delivery systems. , 2012, Journal of pharmaceutical sciences.

[7]  S. Yuk,et al.  Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. , 2004, International journal of pharmaceutics.

[8]  K. Sako,et al.  Timed-release formulation to avoid drug-drug interaction between diltiazem and midazolam. , 2003, Journal of pharmaceutical sciences.

[9]  G. Amidon,et al.  Pharmacokinetics of the CYP 3A Substrate Simvastatin following Administration of Delayed Versus Immediate Release Oral Dosage Forms , 2008, Pharmaceutical Research.

[10]  T. Rades,et al.  Precipitation of a poorly soluble model drug during in vitro lipolysis: characterization and dissolution of the precipitate. , 2010, Journal of pharmaceutical sciences.

[11]  W. Charman,et al.  Lipid-based vehicles for the oral delivery of poorly water soluble drugs , 1997 .

[12]  H. Kristensen,et al.  A dynamic in vitro lipolysis model. II: Evaluation of the model. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[13]  Bradley D Anderson,et al.  What determines drug solubility in lipid vehicles: is it predictable? , 2008, Advanced drug delivery reviews.

[14]  Ben J. Boyd,et al.  Drug Solubilization Behavior During in Vitro Digestion of Simple Triglyceride Lipid Solution Formulations , 2004, Pharmaceutical Research.

[15]  D. Hauss Oral lipid-based formulations. , 2007, Advanced drug delivery reviews.

[16]  Terje R Pedersen,et al.  Simvastatin: a review , 2004, Expert opinion on pharmacotherapy.

[17]  R. Mckinnon,et al.  Localization Of Cytochromes P450 In Human Tissues: Implications for chemical toxicity , 1996, Pathology.

[18]  Brahmeshwar Mishra,et al.  Lipid--an emerging platform for oral delivery of drugs with poor bioavailability. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[19]  J. Vermant,et al.  Formulate-ability of ten compounds with different physicochemical profiles in SMEDDS. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[20]  D. Fatouros,et al.  Clinical studies with oral lipid based formulations of poorly soluble compounds , 2007, Therapeutics and clinical risk management.

[21]  Yuichi Sugiyama,et al.  Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. , 2006, Pharmacology & therapeutics.

[22]  J. Kovarik,et al.  Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. , 1994, Journal of pharmaceutical sciences.

[23]  R Holm,et al.  Supersaturated Self-Nanoemulsifying Drug Delivery Systems (super-SNEDDS) , 2012 .

[24]  C. Porter,et al.  Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs , 2007, Nature Reviews Drug Discovery.

[25]  H. Kristensen,et al.  Solubilisation of poorly water-soluble drugs during in vitro lipolysis of medium- and long-chain triacylglycerols. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[26]  R. Strickley Solubilizing Excipients in Oral and Injectable Formulations , 2004, Pharmaceutical Research.

[27]  Thierry F. Vandamme,et al.  Nano-emulsions and Micro-emulsions: Clarifications of the Critical Differences , 2011, Pharmaceutical Research.

[28]  Joachim Grevel,et al.  Influence of a Fat-Rich Meal on the Pharmacokinetics of a New Oral Formulation of Cyclosporine in a Crossover Comparison with the Market Formulation , 2004, Pharmaceutical Research.

[29]  Christopher J H Porter,et al.  Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies. , 2008, Advanced drug delivery reviews.

[30]  A. Fahr,et al.  Drug delivery strategies for poorly water-soluble drugs , 2007, Expert opinion on drug delivery.